贝伐珠单抗应用于恶性胶质瘤的研究进展  

Advances of bevacizumab in the treatment of glioblastoma

作　　者：沈西宅 李庆云 叶盛英[1] SHEN Xizhai;LI Qingyun;YE Shengying(Pharmaceutical Department,983 Hospital of the Joint Logistics Support Force of the Chinese People’s Liberation Army,Tianjin,300142,China)

机构地区：[1]中国人民解放军联勤保障部队第983医院药剂科,天津300142

出　　处：《肿瘤药学》2023年第6期709-713,共5页Anti-Tumor Pharmacy

摘　　要：恶性胶质瘤是成人最常见的具有侵袭性的原发性脑肿瘤。恶性胶质瘤患者尽管通过手术、放疗和替莫唑胺化疗进行了最佳治疗,但肿瘤仍有很大可能复发,预后效果较差。恶性胶质瘤通常高度血管化。过去几十年中,肿瘤血管生成机制的研究取得了重大进展。抗血管内皮生长因子抗体贝伐珠单抗在复发性胶质细胞瘤中显示出较强活性。本文对贝伐珠单抗治疗恶性胶质瘤的原理和研究进展进行综述,期望能够为贝伐珠单抗的临床应用提供有力的科学依据。Glioblastoma are the most common and aggressive primary brain tumors in adults.Despite optimal treatment with surgery,radiotherapy,and temozolomide chemotherapy,patients with malignant gliomas are still at high risk of tumor recurrences and have poor prognoses.Malignant gliomas are often highly vascularized.But in the last few decades,signifi-cant advances have been made in the study of the mechanisms of tumor angiogenesis.Bevacizumab,an antibody against vascular endothelial growth factor,has demonstrated significant activity in recurrent glioblastomas.Thus in this article,we reviewed the principles and research progress of bevacizumab in the treatment of malignant gliomas,hoping to provide a strong scientific basis for the clinical application of bevacizumab.

关 键 词：恶性胶质瘤 贝伐珠单抗 抗血管生成 血管内皮生长因子 

分 类 号：R739.41[医药卫生—肿瘤]